Citation Impact
Citing Papers
FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study
2003 Standout
Cediranib Plus FOLFOX/CAPOX Versus Placebo Plus FOLFOX/CAPOX in Patients With Previously Untreated Metastatic Colorectal Cancer: A Randomized, Double-Blind, Phase III Study (HORIZON II)
2012
A Randomized Phase II Trial of Vismodegib versus Placebo with FOLFOX or FOLFIRI and Bevacizumab in Patients with Previously Untreated Metastatic Colorectal Cancer
2012
Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update
2011 Standout
Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
2008 Standout
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial
2007 Standout
Relationship of Circulating Tumor Cells to Tumor Response, Progression-Free Survival, and Overall Survival in Patients With Metastatic Colorectal Cancer
2008
The Role of Maintenance Strategies in Metastatic Colorectal Cancer
2019
A colorectal cancer classification system that associates cellular phenotype and responses to therapy
2013
Cancer treatment and survivorship statistics, 2022
2022 Standout
Peripheral neurotoxicity of oxaliplatin in combination with 5-fluorouracil (FOLFOX) or capecitabine (XELOX): a prospective evaluation of 150 colorectal cancer patients
2012
EGFR Antagonists in Cancer Treatment
2008 Standout
Treatment Decisions After Diagnosis of Metastatic Colorectal Cancer
2011
Pancreatic cancer
2004 Standout
K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
2008 Standout
Quality of life, mucositis, and xerostomia from radiotherapy for head and neck cancers: A report from the NCIC CTG HN2 randomized trial of an antimicrobial lozenge to prevent mucositis
2005
5-Fluorouracil incorporation into RNA and DNA in relation to thymidylate synthase inhibition of human colorectal cancers
2004
Perspectives on cancer therapy-induced mucosal injury
2004 Standout
Advanced colorectal cancer: ESMO Clinical Practice Guidelines for treatment
2010
Cancer nanotechnology: The impact of passive and active targeting in the era of modern cancer biology
2013 Standout
A meta-analysis comparing the efficacy of four 5-HT3-receptor antagonists for acute chemotherapy-induced emesis
2007
Amifostine
2001
Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer
2006
Cancer drug resistance: an evolving paradigm
2013 Standout
The resurgence of platinum-based cancer chemotherapy
2007 Standout
An open phase I study assessing the feasibility of the triple combination: oxaliplatin plus irinotecan plus leucovorin/ 5-fluorouracil every 2 weeks in patients with advanced solid tumors
2003
Influence of tumour micro-environment heterogeneity on therapeutic response
2013 StandoutNature
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy
2014 Standout
The mini-driver model of polygenic cancer evolution
2015 StandoutNobel
Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer
2004 Standout
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
2009 Standout
Chemotherapy-induced peripheral neurotoxicity (CIPN): An update
2011
Colorectal cancer
2013 Standout
Current and future perspectives of liquid biopsies in genomics-driven oncology
2018 Standout
Molecular mechanisms of cisplatin resistance
2011 Standout
Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis
2014 Standout
Phase II study of reintroduction of oxaliplatin for advanced colorectal cancer in patients previously treated with oxaliplatin and irinotecan: RE-OPEN study
2015
Estimation of an optimal radiotherapy utilization rate for gastrointestinal carcinoma
2004
Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer
2004 Standout
PEGylation as a strategy for improving nanoparticle-based drug and gene delivery
2015 Standout
Efficacy and tolerability of chemotherapy in elderly patients with advanced oesophago-gastric cancer: A pooled analysis of three clinical trials
2006
Analyses of clinicopathological, molecular, and prognostic associations of KRAS codon 61 and codon 146 mutations in colorectal cancer: cohort study and literature review
2014
Advances and Challenges of Liposome Assisted Drug Delivery
2015 Standout
2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours
2010 Standout
Annual report to the nation on the status of cancer, 1975‐2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates
2009 Standout
Ligand-targeted particulate nanomedicines undergoing clinical evaluation: Current status
2013
Unraveling the therapeutic potential of the Hedgehog pathway in cancer
2013 Standout
EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours
2006
Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
2012 Standout
Gastric cancer
2020 Standout
Effect of Duloxetine on Pain, Function, and Quality of Life Among Patients With Chemotherapy-Induced Painful Peripheral Neuropathy
2013 Standout
Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2010 Standout
Lymphatic Drainage of the Peritoneal Space: A Pattern Dependent on Bowel Lymphatics
2006 StandoutNobel
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy
2020 Standout
Fusobacterium nucleatum Promotes Chemoresistance to Colorectal Cancer by Modulating Autophagy
2017 Standout
Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
2008 Standout
Long-term patient survival in ANCA-associated vasculitis
2010 Standout
VEGF in Signaling and Disease: Beyond Discovery and Development
2019 Standout
Discrepancy between the NCI-CTCAE and DEB-NTC scales in the evaluation of oxaliplatin-related neurotoxicity in patients with metastatic colorectal cancer
2011
Gemcitabine Combined With Oxaliplatin in Advanced Pancreatic Adenocarcinoma: Final Results of a GERCOR Multicenter Phase II Study
2002
5-Fluorouracil Incorporated into DNA Is Excised by the Smug1 DNA Glycosylase to Reduce Drug Cytotoxicity
2007 StandoutNobel
Improved Overall Survival With Oxaliplatin, Fluorouracil, and Leucovorin As Adjuvant Treatment in Stage II or III Colon Cancer in the MOSAIC Trial
2009 Standout
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
2011 Standout
Antiemetic medication for prevention and treatment of chemotherapy-induced nausea and vomiting in childhood
2016
Clinical Practice Guideline for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer: 2010 Update by the Infectious Diseases Society of America
2011 Standout
Chemotherapy for advanced gastric cancer
2017 Standout
OPTIMOX1: A Randomized Study of FOLFOX4 or FOLFOX7 With Oxaliplatin in a Stop-and-Go Fashion in Advanced Colorectal Cancer—A GERCOR Study
2006
NCCN Task Force Report: Management of Neuropathy in Cancer
2009
Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline
2014 Standout
The role of radiotherapy in cancer treatment
2005 Standout
Open-Label Phase III Trial of Panitumumab Plus Best Supportive Care Compared With Best Supportive Care Alone in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer
2007 Standout
Neuroprotective Effect of Reduced Glutathione on Oxaliplatin-Based Chemotherapy in Advanced Colorectal Cancer: A Randomized, Double-Blind, Placebo-Controlled Trial
2002
Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer
2018 Standout
Randomized Trial of Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy Versus Systemic Chemotherapy and Palliative Surgery in Patients With Peritoneal Carcinomatosis of Colorectal Cancer
2003 Standout
Cannabinoids for Medical Use
2015 Standout
Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200
2007 Standout
Evolving Treatment of Advanced Colon Cancer
2009
Multivariate Prognostic Factor Analysis in Locally Advanced and Metastatic Esophago-Gastric Cancer—Pooled Analysis From Three Multicenter, Randomized, Controlled Trials Using Individual Patient Data
2004
Superiority of Oxaliplatin and Fluorouracil-Leucovorin Compared With Either Therapy Alone in Patients With Progressive Colorectal Cancer After Irinotecan and Fluorouracil-Leucovorin: Interim Results of a Phase III Trial
2003
Genotype-Driven Phase I Study of Irinotecan Administered in Combination With Fluorouracil/Leucovorin in Patients With Metastatic Colorectal Cancer
2009
Cytoreductive Surgery Combined With Perioperative Intraperitoneal Chemotherapy for the Management of Peritoneal Carcinomatosis From Colorectal Cancer: A Multi-Institutional Study
2004 Standout
Works of May Mabro being referenced
Can Chemotherapy Be Discontinued in Unresectable Metastatic Colorectal Cancer? The GERCOR OPTIMOX2 Study
2009
Panitumumab combined with irinotecan for patients with KRAS wild-type metastatic colorectal cancer refractory to standard chemotherapy: a GERCOR efficacy, tolerance, and translational molecular study
2012
Bimonthly Leucovorin, Infusion 5-Fluorouracil, Hydroxyurea, and Irinotecan (FOLFIRI-2) for Pretreated Metastatic Colorectal Cancer
2003
A Risk-Benefit Assessment of Amifostine in Cytoprotection
1999
CPT-11 (Irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer
1999
Prognostic Factor Analysis in Advanced Gastric Cancer Patients Treated with Hydroxyurea, Leucovorin, 5-Fluorouracil, and Cisplatin (HLFP Regimen)
2003
Optimisation of 5-fluorouracil (5-FU)/cisplatin combination chemotherapy with a new schedule of hydroxyurea, leucovorin, 5-FU and cisplatin (HLFP regimen) for metastatic oesophageal cancer
2002
Final results of OPTIMOX2, a large randomized phase II study of maintenance therapy or chemotherapy-free intervals (CFI) after FOLFOX in patients with metastatic colorectal cancer (MRC): A GERCOR study
2007
Evaluation of oxaliplatin dose intensity in bimonthly leucovorin and 48-hour 5-fluorouracil continuous infusion regimens (FOLFOX) in pretreated metastatic colorectal cancer
2000
[Oral granisetron solution as prophylaxis for chemotherapy-induced emesis in children: double-blind study of 2 doses].
2000
[Comparative trial of oral granisetron and intravenous ondansetron in patients receiving chemotherapy for breast cancer. Study Group of Granisetron].
1999
Oxaliplatin reintroduction in patients previously treated with leucovorin, fluorouracil and oxaliplatin for metastatic colorectal cancer
2004
High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX 7)
2001
Adjuvant chemotherapy versus perioperative chemotherapy (CTx) for resectable gastric signet ring cell (SRC) gastric cancer: A multicenter, randomized phase II study (PRODIGE 19).
2019